Peyronie's Disease

Nehra, Ajay; Mulhall, John P.

doi:10.1002/9780470755235.ch14

Our system is currently under heavy load due to increased usage. We're actively working on upgrades to improve performance. Thank you for your patience.

Standard Practice in Sexual Medicine 2006

DOI: 10.1002/9780470755235.ch14

|View full text |Cite

Peyronie's Disease

Ajay Nehra¹,

John P. Mulhall²

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2010

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 102 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy

González‐Cadavid

Rajfer

2010

Nat Rev Urol

View full text Add to dashboard Cite

Peyronie's disease (PD) is a localized fibrotic condition of the tunica albuginea that is associated with risk factors for corpora cavernosa fibrosis (such as advanced age and diabetes) and Dupuytren contracture, another localized fibrotic process. Most of the current pharmacological treatments for PD are not based on antifibrotic approaches that have shown promising results in animal models and clinical efficacy in other fibrotic conditions, which may explain why they are generally unsuccessful. Evidence gathered in human specimens and animal models of PD have elucidated aspects of its etiology and histopathology, showing that overexpression of transforming growth factor beta1, plasminogen activator inhibitor 1, reactive oxygen species and other profibrotic factors, which are, in most cases, assumed to be induced by trauma to the tunica albuginea, leads to myofibroblast accumulation and excessive deposition of collagen. At the same time, a steady overexpression of inducible nitric oxide synthase, leading to increased nitric oxide and cGMP levels, seems to act as an endogenous antifibrotic mechanism. This process has also been reported in corporal and cardiovascular fibrosis, and has led to the demonstration that long-term continuous administration of phosphodiesterase type 5 inhibitors counteracts the development of a PD-like fibrotic plaque in a rat model, and later extended to the prevention of corporal fibrosis in animal models of erectile dysfunction.

show abstract

Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy

González‐Cadavid

Rajfer

2010

Nat Rev Urol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

hi@scite.ai

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

Peyronie's Disease

Cited by 1 publication

References 102 publications

Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy

Treatment of Peyronie's disease with PDE5 inhibitors: an antifibrotic strategy

Contact Info

Product

Resources

About